What Ultraproct L 2% Treats: Main Uses and Benefits

Ultraproct L 2% Rectal Cream is a medication indicated for the short-term symptomatic relief of discomfort and inflammation in the anorectal area. The medicine is utilized for the symptomatic relief associated with conditions such as haemorrhoids, non-infectious proctitis, and anal eczema in adult patients.

This formulation contains ingredients intended to help alleviate pain, soreness, and contribute to reducing localised inflammation and swelling. The treatment goal is to contribute to a reduction in localised pain, itching, and burning sensations, which addresses common clinical presentations in proctology.

As part of its therapeutic application, the treatment is intended for limited application:

“The overall duration of treatment is typically restricted.”

---

Quick Fact: Relief for Localised Discomfort

Ultraproct L 2% Rectal Cream is a prescription medicine with specific population-based eligibility rules defined by official regulatory authorities. Use is generally established for adult patients requiring short-term symptomatic relief.

Contraindications (Who Must Not Use)

The medicine is strictly contraindicated if a patient has a known hypersensitivity or allergy to either active ingredient (Fluocortolone or Lidocaine Hydrochloride) or any excipients.

Furthermore, use is prohibited for patients suffering from local infectious processes in the treatment area, including those of viral origin (such as herpes simplex or chickenpox), tuberculous processes, or syphilitic conditions. For primary bacterial or fungal infections, the medicine must not be used unless accompanied by concurrent, appropriate anti-infective therapy, as officially stated.

Age and Reproductive Status Restrictions

Ultraproct L 2% is not recommended for use in children and adolescents under 18 years of age due to insufficient data supporting safety and efficacy in these younger populations.

Regarding reproductive status, the medicine should not be applied during the first trimester of pregnancy. In later trimesters and during breastfeeding, use is generally not recommended for long periods or over large areas, requiring careful clinical review of benefits versus risks.

Interactions with other medicines and products

The official interaction profile for Ultraproct L 2% is structured around potential systemic exposure risks from its two active ingredients, Fluocortolone and Lidocaine Hydrochloride, as defined by government regulatory documents.

Pharmacokinetic (Exposure-Altering) Interactions

Co-treatment with potent CYP3A inhibitors, such as cobicistat-containing products or ritonavir, is documented to interfere with the metabolism of the Fluocortolone component. These substances reduce the clearance of Fluocortolone, which is expected to increase the potential for systemic exposure and raise the risk of systemic corticosteroid side-effects. Official regulatory documents specify that this combination should be avoided unless the expected benefit justifies the increased risk, in which case strict patient monitoring is required.

Pharmacodynamic (Additive) Interactions

The Lidocaine component carries documented risks of additive effects when co-administered with other agents. Concomitant use with other local anaesthetics or Class Ib antiarrhythmic drugs may result in additive toxic effects on the central nervous and cardiovascular systems. Additionally, patients using Class III antiarrhythmic drugs (such as amiodarone) require careful supervision due to the potential for additive cardiac effects.

Regulatory Context Constraint

It is formally stated in prescribing information that while certain systemic drug interactions are known for the components, these interactions are not considered clinically relevant when the topical product is used for a short duration at recommended doses.

Ultraproct L 2% utilizes two pharmacologically active compounds acting via distinct biochemical pathways.

Fluocortolone pivalate, a corticosteroid, binds to intracellular glucocorticoid receptors, modulating gene expression to suppress pro-inflammatory cytokine and mediator release. This inhibition includes the synthesis and liberation of prostaglandins and leukotrienes, eicosanoids that mediate local inflammation, vascular permeability, and cellular migration. The resulting anti-inflammatory activity leads to reduced local vascular permeability and diminished cellular exudate.

Cinchocaine hydrochloride is a local anesthetic that reversibly binds to voltage-gated sodium channels on the neuronal membrane. This interaction blocks the channels, thereby inhibiting the influx of sodium ions required for action potential initiation and propagation in afferent nerve fibers.

How to use Ultraproct L 2% Ointment

Ultraproct L 2% (fluocortolone pivalate, fluocortolone caproate, and cinchocaine hydrochloride) is typically used for the short-term treatment of internal and external hemorrhoids, anal fissures, and proctitis. Always adhere strictly to the dosage and duration prescribed by your healthcare provider.

Application Guidelines

Before application, the anal region should be thoroughly cleaned, preferably after a bowel movement. Wash your hands thoroughly both before and after using the product.

Usage Area	Application Method	Initial Dosage (Typical)	Maintenance Dosage
External	Apply a pea-sized amount with a finger and smear thinly around the anus. For protruding lumps, apply thickly and gently press them back in.	Twice daily (up to four times on the first day for fast relief)	Once daily for at least one week after symptoms disappear
Internal	Screw the enclosed applicator nozzle onto the tube. Insert the nozzle carefully into the rectum and gently squeeze the tube while slowly withdrawing the nozzle. Clean the nozzle with warm, soapy water after each use.	Twice daily (up to four times on the first day for fast relief)	Once daily for at least one week after symptoms disappear

Duration of Use and Precautions

• The duration of treatment should not exceed four weeks.
• Even with rapid improvement, continue treatment for at least one week at a reduced frequency (once daily) to help prevent relapse.
• Avoid accidental contact with the eyes. Rinse immediately with cold water if contact occurs.
• If you are pregnant or breastfeeding, the clinical benefit must be carefully weighed against potential risks before use.

Research Evidence / Overview of Studies for Ultraproct L 2%

---

Evidence for Use in Acute Haemorrhoids

The core research for the combined medicine Ultraproct L 2% (Fluocortolone and Lidocaine Hydrochloride) research examined conditions characterized by fluctuating or episodic manifestations, such as acute haemorrhoids. Researchers used both Randomized Controlled Trials (RCTs) investigating comparable fixed combinations and large-scale observational studies in real-world settings to monitor changes in the observed populations. The populations was studied for consisted primarily of adult patients with acute or exacerbated chronic haemorrhoids.

These studies focused on outcomes related to physical discomfort, monitoring patient-reported experiences like pain, itching, bleeding, and overall perceived discomfort. Where comparative trials exist for the class, the medication was observed in comparison to a placebo or the base formulation. Findings describe patterns related to symptoms observed during the study period over the short-term course of treatment.

---

Evidence for Use in Non-infectious Proctitis and Anal Eczema

Ultraproct L 2% studies explored data derived from the active component in localized inflammatory conditions, specifically non-infectious proctitis (inflammation of the rectum) and anal eczema. Evidence for these uses often relies on data derived from studies examining the topical corticosteroid component (Fluocortolone) for localized inflammatory or irritative states. The studies monitored outcomes linked to inflammatory or irritative states, such as changes in the degree of localized swelling and related discomfort. The available evidence provides insight into short-term changes over short induction phases.

Specific Randomized Controlled Trials (RCTs) for the Fluocortolone/Lidocaine combination directly targeting these conditions are still emerging. Therefore, the data for these uses appears to be highly reliant on extrapolation from the established use of the core medication class, and certainty remains low compared to the haemorrhoid data.

---

What is Still Uncertain About Ultraproct L 2%

A comprehensive review of the evidence highlights several areas where certainty remains low or research is still needed. The major research limitation frames include that follow-up durations were limited in most primary studies (typically 14 days), meaning long-term outcomes are not well characterized. Comparative evidence is lacking in some areas, and the reliance on observational study designs means that research provides context but not individual predictions of a cause-and-effect relationship. Data for certain groups remain insufficient, including for children, adolescents, and the older adult population.

Key Studies & References

1. Package leaflet: Information for the user - Ultraproct® 0.92 mg/g + 0.95 mg/g + 5 mg/g Rectal Ointment (Authoritative Regulatory Information)
2. A Systematic Review of the Topical Drugs for Post Hemorrhoidectomy Pain (Supports the general class evidence and short-term focus)

Common questions about Ultraproct L 2% (FAQ)

Q: Is Ultraproct L 2% safe to use for a long time?

The duration of treatment should be kept as short as possible. Use is typically limited to a few weeks, as directed by a healthcare professional. Prolonged or extensive use of topical corticosteroids may increase the risk of certain side effects.

Q: What should I do if I miss a dose of Ultraproct L 2%?

If a dose is missed, it should generally be applied as soon as you remember, unless it is almost time for the next scheduled application. Do not apply a double amount to make up for a forgotten dose. Consistency with your prescribed schedule is important.

Q: Can Ultraproct L 2% be used during pregnancy or while breastfeeding?

Use during pregnancy or breastfeeding requires careful consideration. A healthcare provider is best positioned to assess the potential benefits against any possible risks based on your specific situation. Discuss any concerns with your doctor before use.

Q: How should I store Ultraproct L 2%?

Ultraproct L 2% should be stored at room temperature, away from heat and moisture. Keep the product in its original container and out of the reach of children. Check the product label for specific temperature guidance.

How to Store and Dispose of Ultraproct Rectal Ointment

Official regulatory documents define specific conditions for storing and disposing of Ultraproct Rectal Ointment to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store below 25 C and do not exceed this temperature.
Safety	Keep the ointment out of the sight and reach of children.
Container Integrity	Replace the cap tightly after each use.
In-Use Stability	Use the ointment within 3 months of first opening the tube.

Disposal Guidelines

Expired or unused Ultraproct must not be discarded via wastewater or household waste. Individuals must consult with a pharmacist on the proper method for disposal of any leftover or expired medicine.